These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 7028255

  • 1. Cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced non-small cell lung cancer.
    Knost JA, Greco FA, Hande KR, Richardson RL, Fer MF, Oldham RK.
    Cancer Treat Rep; 1981; 65(11-12):941-5. PubMed ID: 7028255
    [Abstract] [Full Text] [Related]

  • 2. Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma.
    Evans WK, Feld R, DeBoer G, Osoba D, Curtis JE, Baker MA, Myers RE, Quirt IC, Pritchard KI, Brown TC, Kutas GJ, Blackstein ME, Ottema B, Millband L.
    Cancer Treat Rep; 1981; 65(11-12):947-54. PubMed ID: 7028256
    [Abstract] [Full Text] [Related]

  • 3. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer.
    Kelsen D, Gralla R, Stoopler M, Casper E, Cheng E, Kosloff C, Golbey R.
    Cancer Treat Rep; 1982 Feb; 66(2):247-51. PubMed ID: 7034932
    [Abstract] [Full Text] [Related]

  • 5. Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung.
    Davis S, Rambotti P, Park YK.
    Cancer Treat Rep; 1981 Feb; 65(11-12):955-8. PubMed ID: 7028257
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 12. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [Abstract] [Full Text] [Related]

  • 13. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
    Ueoka H, Kiura K, Tabata M, Kamei H, Gemba K, Sakae K, Hiraki Y, Hiraki S, Segawa Y, Harada M.
    Cancer; 1998 Jul 15; 83(2):283-90. PubMed ID: 9669811
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma.
    Campbell M, Baker LH, Opipari M, Al-Sarraf M.
    Cancer Treat Rep; 1981 Jul 15; 65(9-10):897-9. PubMed ID: 7196800
    [Abstract] [Full Text] [Related]

  • 15. Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586).
    Yuen AR, Fuks JZ, Ettinger DS, Chang AY, Ruckdeschel JC, Phan SC, Blum RH.
    Cancer J Sci Am; 2000 Jul 15; 6(1):34-9. PubMed ID: 10696737
    [Abstract] [Full Text] [Related]

  • 16. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D, Golubicic I, Gavrilovic D, Kezic I, Jelic S.
    J BUON; 2009 Jul 15; 14(2):203-9. PubMed ID: 19650167
    [Abstract] [Full Text] [Related]

  • 17. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
    Masutani M, Ochi Y, Kadota A, Akusawa H, Kisohara A, Takahashi N, Koya Y, Horie T.
    Oncol Rep; 2000 Jul 15; 7(2):305-10. PubMed ID: 10671676
    [Abstract] [Full Text] [Related]

  • 18. Combination chemotherapy for small cell lung cancer.
    Sufarlan AW, Zainudin BM.
    Med J Malaysia; 1993 Jun 15; 48(2):166-70. PubMed ID: 8394502
    [Abstract] [Full Text] [Related]

  • 19. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
    Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, Gilligan D, Murray PA, Ruiz de Elvira MC, O'Donnell KM, Gower NH, Harper PG, Hackshaw AK, London Lung Cancer Group.
    J Clin Oncol; 2006 Aug 20; 24(24):3823-30. PubMed ID: 16921033
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD, Ramlau R, Hansen O, Lorusso V, Wagner L, Barni S, Cristovao MM, Huber R, Alberola V, Mitrovic M, Colin C, Gasmi J.
    Lung Cancer; 2005 Apr 20; 48(1):129-35. PubMed ID: 15777980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.